A Novel Frameshift COL3A1 Variant in Vascular Ehlers-Danlos Syndrome

Ann Vasc Surg. 2019 Nov:61:472.e9-472.e13. doi: 10.1016/j.avsg.2019.05.057. Epub 2019 Aug 5.

Abstract

Ehlers-Danlos syndromes (EDSs) are a group of heritable connective tissue disorders with distinct genetic etiologies. Of the 13 currently recognized types of EDS, the vascular type EDS (vEDS) is generally considered the most severe and is associated with a decreased life expectancy due to spontaneous arterial, intestinal, and or uterine rupture. Diagnosis of vEDS is supported by genetic testing confirming the presence of pathogenic variations in COL3A1, a type III procollagen gene. Management of vEDS is usually conservative with control of hemodynamic stress, frequent cardiovascular imaging, and, if indicated, a thoughtful endovascular intervention or surgical repair. We present a novel frameshift variant in COL3A1 leading to vEDS with multiple vascular involvements. Based on our literature review, this variant has not been reported and may result in a less severe form of vEDS. Our case report provides insight into genetic variants and clinical expression of vEDS.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Aspirin / therapeutic use
  • Collagen Type III / genetics*
  • Ehlers-Danlos Syndrome / diagnosis
  • Ehlers-Danlos Syndrome / genetics*
  • Ehlers-Danlos Syndrome / therapy
  • Fluid Therapy
  • Frameshift Mutation*
  • Genetic Predisposition to Disease
  • Humans
  • Male
  • Phenotype
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • COL3A1 protein, human
  • Collagen Type III
  • Aspirin